Quotes 5-day view Delayed Nyse
11/29/2021
11/30/2021
12/01/2021
12/02/2021
12/03/2021
Date
254.83(c)
248.04(c)
249.13(c)
247.88(c)
245.58(c)
Last
4 041 677
8 265 918
3 241 515
3 817 784
4 125 045
Volume
-2.13% -2.66% +0.44% -0.50% -0.93% Change
Estimated financial data (e) (USD)
Sales 2021
27 480 M - -
Net income 2021
6 130 M - -
Net Debt 2021
12 164 M - -
P/E ratio 2021
36,5x
Yield 2021
1,34%
Sales 2022
27 860 M - -
Net income 2022
7 001 M - -
Net Debt 2022
9 715 M - -
P/E ratio 2022
31,6x
Yield 2022
1,46%
Capitalization
223 B 223 B -
EV / Sales 2021
8,54x
EV / Sales 2022
8,34x
Nbr of Employees
35 000
Free-Float
99,8%
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products...
Ratings of Eli Lilly and Company
All news about ELI LILLY AND COMPANY
12/03 FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly RE
12/03 Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody T.. MT
12/03 Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVI.. MT
12/03 FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infant.. DJ
12/03 Eli Lilly Sees FDA Granting EUA of Two Monoclonal Antibodies for Treatment of COVID in .. MT
12/03 AbCellera Biologics Names New Chief Commercial Officer MT
12/03 Eli Lilly, Innovent Biologics' Cancer Drug Added to China's Updated National Reimbursem.. MT
12/03 Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL.. AQ
12/02 Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sin.. CI
12/02 Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants RE
12/02 What COVID-19 vaccine and drug makers have to say about Omicron RE
12/01 Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment C.. PR
11/30 US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi.. MT
11/30 CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..MT
11/30 Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr.. MT
News in other languages on ELI LILLY AND COMPANY
Analyst Recommendations on ELI LILLY AND COMPANY
Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
Chart ELI LILLY AND COMPANY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ELI LILLY AND COMPANY
Short Term Mid-Term Long Term Trends Bearish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
245,58 $
Average target price
273,42 $
Spread / Average Target
11,3%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
